NEW DELHI: In what could be good news for patients, Indian Patent Office (IPO) has rejected MNC AbbVie’s patent application for its blockbuster cancer drug Venetoclax citing lack of inventive step.
ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as soon as they’re published. ProPublica on Friday published never-before-released data ...
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...
Albertans may see more and less-expensive varieties of Ozempic on the market soon, after a patent on the drug expired two weeks ago. Ozempic has made headlines in recent years as a popular weight-loss ...
ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as soon as they’re published. Join us Jan. 14 for a virtual discussion about our Rx ...
Share on Pinterest The FDA recently approved a generic abortion pill that’s considered as safe and effective as mifepristone. Shuran Huang for The Washington Post via Getty Images The approval, ...
AbbVie settles with generic Rinvoq hopefuls, shielding the immunology med's US stronghold until 2037
With Rinvoq and its sibling medicine Skyrizi having successfully picked up the sales torch in the wake of Humira’s tumble over the patent cliff, AbbVie is working to cover its legal bases so the ...
German generics maker Stada has settled on a buyout by CapVest Partners, putting an end to its previously reported IPO ambitions. The CapVest deal changes Stada’s ownership from private equity firms ...
Some Chinese companies now catapulting ahead to make generic versions of Novo Nordisk's Wegovy also provided ingredients for more than a billion makeshift doses of weight-loss drugs sold online in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results